Viralgen

Viralgen Names Bayer's Angela Ochoa Chico CEO as Vanhove Exits

San Sebastián – – October 19, 2026 -- Viralgen, the AAV gene therapy contract manufacturer owned by Bayer unit AskBio, has appointed Bayer executive Angela Ochoa Chico as chief executive effective January 1, 2027, replacing Jimmy Vanhove after four years in the role.

Vanhove moves to lead Bayer's U.S. pharmaceutical supply network expansion

Vanhove will lead the development and expansion of Bayer's U.S. Pharmaceutical Product Supply Network, based in New Albany, Ohio. He will join the Pharmaceuticals Division's Product Supply Leadership Team.

EpilepsyGTx Taps Viralgen to Scale AAV Gene Therapy EPY201

London and San Sebastián, Spain – September 13, 2026 -- EpilepsyGTx has partnered with AAV-focused CDMO Viralgen to manufacture EPY201, an investigational gene therapy targeting focal refractory epilepsy (FRE), a condition affecting an estimated 10 million patients worldwide, including 2 million across the US, UK and EU.

Viralgen's Aava platform will scale EPY201 production ahead of first-in-human trials

Under the agreement, Viralgen will deploy its proprietary Aava manufacturing platform to produce EPY201 at scale. The platform has already supported production of 1,500 AAV batches and is designed to handle all AAV serotypes with high-yield output. Viralgen's San Sebastián facility operates three cGMP suites, each with 2,000-liter capacity, certified by AEMPS/EMA, alongside plasmid production, process optimization, fill-finish and internal QC testing.